![]() Sleep disturbance in bipolar disorder across the lifespan. Profiles of “manic” symptoms in bipolar I, bipolar II and major depressive disorders. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, Petukhova M, et al. Treatment options for insomnia in schizophrenia: a systematic review. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Psychotic and bipolar disorders: schizophrenia. Clinical guideline for the evaluation and management of chronic insomnia in adults. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Drug-induced insomnia and excessive sleepiness. DSM-5 cannabis withdrawal syndrome: demographic and clinical correlates in U.S. Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. Recreational cannabis use: pleasures and pitfalls. Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. Endorsement of DSM-IV dependence criteria among caffeine users. Hughes JR, Oliveto AH, Liguori A, Carpenter J, Howard T. Polysomnographic sleep disturbances in nicotine, caffeine, alcohol, cocaine, opioid, and cannabis use: a focused review: polysomnographic changes in substance use. ![]() Insomnia in alcohol-dependent patients: prevalence, risk factors and acamprosate effect: an individual patient data meta-analysis. Alcohol withdrawal syndrome: benzodiazepines and beyond. Washington, DC: American Psychiatric Association 2022. Diagnostic and statistical manual of mental disorders. “Substance/Medication-Induced Sleep Disorder” in American Psychiatric Association. Generalized anxiety disorder: diagnosis and treatment. Prevalence of insomnia and associated factors in outpatients with generalized anxiety disorder treated in psychiatric clinics. 2019 170(7):ITC49–64.įerre Navarrete F, Pérez Páramo M, Fermin Ordoño J, López Gómez V. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Understanding recent insights in sleep and posttraumatic stress disorder from a research domain criteria (RDoC) framework. “Sleep-Wake Disorders” in American Psychiatric Association. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Hirshkowitz M, Whiton K, Albert SM, Alessi C, Bruni O, DonCarlos L, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. ![]() Riemann D, Spiegelhalder K, Feige B, Voderholzer U, Berger M, Perlis M, et al. Principles and practice of sleep medicine. In: Kryger MH, Roth T, Dement WC, editors. A behavioral perspective on insomnia treatment. National Institutes of Health State of the Science Conference statement on manifestations and management of chronic insomnia in adults, June 13–15, 2005. Drugs and Insomnia: the use of medications to promote sleep. National Institutes of Health Consensus Development Conference Statement. Atlas of clinical sleep medicine: expert consult - online and print. Given the complexity of insomnia as a symptom, we discuss these secondary effects to some degree, but mainly to clarify the primary issue of sleep disturbance. This chapter also endeavors to isolate sleep disruption as the primary symptom of focus, while definitions of insomnia as a disorder often describe secondary effects and impact on daytime functioning. The routine use of PSG alone to evaluate insomnia is not recommended, but it is important to note that a patient’s sleep report and objective data may not always agree, and the misperception of sleep quality or quantity may be an issue (Kryger, Roth, Dement. Elsevier, 2017). We define insomnia as difficulty initiating sleep, difficulty in maintaining sleep, and/or early morning awakening, resulting in a sleep deficiency despite adequate opportunity for sleep and no change in the patient’s baseline “need for sleep.” Insomnia, therefore, is a symptom, reported in a patient’s history, and there is no standard objective measure of insomnia through polysomnography (PSG) or other means.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |